Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
WATCH: Navigating enablement and written description requirement standards in the USPTO
Americas
On January 10 this year, the director of the USPTO issued new guidelines on enablement under 35 U.S.C §112. In recent years, the landscape of patent law in the United States has undergone a significant shift, with courts adopting a more stringent stance on the criteria of enablement and written description.   5 November 2024
Sandoz lands reduced antitrust award  of $70m
Americas
A US biopharma firm must pay the damages to Sandoz over a long-running dispute over lung therapy | New Jersey district judge had ordered the pair to “meet and confer” in a September judgment, but the parties couldn’t agree.   5 November 2024
New president’s to-do list: Patent bills, non-competes, USPTO director?
Americas
The 47th US president will need to address the thorny issues of non-competes, patent rights and drug pricing.   5 November 2024
Americas
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages.   5 November 2024
Americas
New hire specialises in guiding life sciences and health tech clients through compliance issues | Work includes US regulations, including those enforced by the FDA, Drug Enforcement Administration and the Office of Inspector General.   31 October 2024
Europe
European Commission says fine “proportionate and necessary” after Teva spread misleading information about rival’s product | Teva says it is “deeply disappointed” and will appeal.   31 October 2024
Europe
The government’s autumn budget sends a positive signal but a more comprehensive approach is required to unlock the UK’s potential, says Graeme Moore of Mewburn Ellis.   31 October 2024
Americas
Innovation in the life sciences industries is deeply intertwined with regulatory compliance and intellectual property protection. There is a complex interplay between IP and regulatory laws, creating unique challenges for lawyers working in this field. Join us as the panel discusses the delicate balance between innovation, regulatory requirements and safeguarding IP.   29 October 2024
Americas
UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering haemophilia B therapies in the US, Canada and UK   29 October 2024
Europe
Former head of life sciences at Gowling, joins Cooley’s London office as a partner | Brings expertise in cross-border licensing and collaboration deals in the pharmaceutical, biotech, and medical device sectors.   29 October 2024